FIELD: medicine; pharmacology.
SUBSTANCE: invention describes application of derivatives of 10,10-dialkylprostanic acid as effective ophthalmic antihypertensive agents. Animal suffering from ocular hypertension or glaucoma is introduced with therapeutically effective amount of composition of general formula : where dotted line indicates presence or absence of bond, cross-hatch wedge designates α-configuration and solid triangle designates β-configuration; B is simple, double or triple covalent bond; n - 0-6; X - CH2, S or O; Y is any pharmaceutically acceptable salt of group CO2H, or group CO2R, CONR2, CONHCH2CH2OH, CON (CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, CONR2 or of formula Ia; R - H, C1-6alkyl or C2-6alkenyl; R2 and R3 represent C1-6normal alkyl which can be same or another, and can be connected with each other so that to form ring including carbon atom to which both of them are connected.
EFFECT: invention provides higher efficiency of composition and method of treatment.
52 cl, 1 ex, 2 tbl, 8 dwg
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED CYCLOPENTANS POSSESSING PROSTAGLANDIN ACTIVITY | 2008 |
|
RU2481339C2 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2661197C2 |
COMBINATIONS OF ALPHA-2-DELTA-LIGAND WITH SELECTIVE CYCLOIXYGENASE-2 INHIBITOR | 2003 |
|
RU2286151C2 |
LAXATIVE AGENT COMPOSITION | 2001 |
|
RU2694361C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
THERAPEUTIC SUBSTITUTED CYCLOPENTANES | 2009 |
|
RU2501789C2 |
PURGATIVE AGENT COMPOSITION | 2001 |
|
RU2278666C2 |
HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | 2007 |
|
RU2479575C2 |
DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
Authors
Dates
2008-10-20—Published
2004-02-06—Filed